The first generation of kinase inhibitors, such as breakpoint cluster region-Abelson murine leukemia fusions (BCR-ABL), epidermal growth factor receptor mutations (EGFR), and anaplastic lymphoma kinase rearrangements (ALK), confirmed that they have great therapeutic potential in chronic myeloid leukemia and kinase-driven non-small cell lung cancer (NSCLC) [1,2,3]. Here, ALK is linked to chronic myelogenous leukemia, BCR-ABL1 positive.